BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11380219)

  • 1. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.
    Snyder KM; Stock RG; Hong SM; Lo YC; Stone NN
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):335-41. PubMed ID: 11380219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probability of late rectal morbidity in 125I prostate brachytherapy.
    Waterman FM; Dicker AP
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
    Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy.
    Nakamura R; Kikuchi K; Tanji S; Yabuuchi T; Uwano I; Yamaguchi S; Ariga H; Fujioka T
    Radiat Oncol; 2012 Jan; 7():15. PubMed ID: 22293400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
    Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
    Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
    McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications.
    Han BH; Wallner KE
    Int J Cancer; 2001 Dec; 96(6):372-8. PubMed ID: 11745508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal dosimetric analysis following prostate brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argon plasma coagulation for rectal bleeding after prostate brachytherapy.
    Smith S; Wallner K; Dominitz JA; Han B; True L; Sutlief S; Billingsley K
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):636-42. PubMed ID: 11597803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy.
    Mishra MV; Shirazi R; Barrett WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):397-400. PubMed ID: 17956713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
    Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
    Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
    Crook JM; Potters L; Stock RG; Zelefsky MJ
    Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
    Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
    Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
    Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
    Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.